Halaven: a new breast cancer option

摘要

Eribulin, marketed as Halaven (Eisai), is licensed as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer whose disease has progressed despite them having received two previous chemotherapy options for advanced disease. These options must have included an anthracycline and a taxane unless the patient was not suitable for these treatments.